{
    "nct_id": "NCT06730750",
    "official_title": "A Phase 1/2a, Multicenter, Open-label, First in Human Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors",
    "inclusion_criteria": "* Documented histologically or cytologically confirmed, advanced, unresectable/metastatic solid tumor measurable by RECIST v1.1.\n* CRC: Part 1A, Part 2A-CRC, Part 1B, and Part 2B:.\n\n  i) Locally advanced/metastatic, recurrent, or unresectable CRC with adenocarcinoma histology and whose disease has progressed after systemic cancer therapy in the metastatic or adjuvant setting including 5-FU, irinotecan, and/or oxaliplatin (if available and not contraindicated).\n* NSCLC: Part 2A-NSCLC/GC, 3L+ NSCLC:.\n\n  i) Histologically confirmed NSCLC meeting stage criteria for Stage IIIB, Stage IV, or recurrent disease.\n\nii) Progressed on at least 2 prior lines of therapy,\n\niii) Participants must have received and progressed on or after anti-PD-(L)1 therapy, if available.\n\n- GC: Part 2A-NSCLC/GC, 2L+ GC:.\n\ni) Participants must have received and then progressed or been intolerant to at least 1 standard treatment regimen in the advanced or metastatic setting (or have progressed within 6 months of adjuvant therapy).\n\nii) ECOG performance status of 0 or 1.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of anaphylactic reactions to irinotecan and/or bevacizumab.\n* Previously received therapy targeting CEACAM5.\n* Grade â‰¥ 3 ILD/pneumonitis.\n* Other protocol-defined Inclusion/Exclusion criteria apply.",
    "miscellaneous_criteria": ""
}